This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | MicrobiomeTrials
← Back to trials NCT05552157
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation Recruiting PHASE2, PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-11-22Est. Completion: 2034-03-30
Enrollment target: 280 participantsLocations University of Alabama in Birmingham, Birmingham, Alabama, United States University of California San Diego Medical Center, La Jolla, California, United States University of Southern Califonria, Los Angeles, California, United States Yale University School of Medicine, New Haven, Connecticut, United States Emory University, Atlanta, Georgia, United States Advocate Lutheran General Hospital, Park Ridge, Illinois, United States Indiana University School of Medicine, Indianapolis, Indiana, United States Washington University in St. Louis, St Louis, Missouri, United States New York University Medical Center, New York, New York, United States University of Pittsburgh, Pittsburgh, Pennsylvania, United States Butler Hospital, Providence, Rhode Island, United States Kerwin Research and Memory Center, Dallas, Texas, United States University of Washington, Seattle, Washington, United States Instituto de Investigaciones Neurologicas Raul Carrea, FLENI, Ciudad Autonoma de Buenos Aire, Argentina Neuroscience Research Australia, Randwick, New South Wales, Australia Other microbiome trials you might be interested in Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes (MDS) Myeloproliferative Neoplasm
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and…
Omaha, United States Est. completion Jul 2027
Genetic Predisposition to Disease Healthy Volunteer APOE-4 Positive
Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaq…
Columbia, United States
Alzheimer's Research Australia, Melbourne, Victoria, Australia
UBC Hospital, Vancouver, British Columbia, Canada
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
McGill Center for Studies in Aging, Verdun, Quebec, Canada
CHU de Quebec - Hôpital de l' Enfant Jésus, Québec, Canada
Grupo de Neurociencias Sede de la Universidad de Antioquia, Medellín, Colombia
CHU de Toulouse - Hôpital Purpan, Toulouse, Haute Garonne, France
Hopital Roger Salengro - CHU Lille, Lille, Nord, France
Groupe Hospitalier Pitie-Salpetriere, Paris, Paris, France
Hopital Neurologique Pierre Wertheimer, Bron, Rhone, France
CHU de Rouen - Hôpital Charles Nicolle, Rouen, Seine Maritime, France
Universitaetsklinikum Tubingen, Tübingen, Baden-Wurttemberg, Germany
LMU-Campus Grosshadern, Munich, Bavaria, Germany
IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
Azienda Ospedaliera Universitaria Careggi, Florence, Italy
Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico City, Mexico City, Mexico
Brain Research Center, Amsterdam, Netherlands
New Zealand Brain Research Institute, Christchurch, New Zealand
University of Puerto Rico, School of Medicine, San Juan, Puerto Rico
Asan Medical Center, Seoul, South Korea
Hospital Clínic I Provincial de Barcelona, Barcelona, Spain
The National Hospital for Neurology and Neurosurgery, London, Greater London, United Kingdom Est. completion Dec 31, 2027